Sanofi logo
Sanofi
SNYNF | OTC
Chart Builder DCF Calculator
$77.98
-$2.37 (-2.95%)
At close: Oct 2, 2026, 2:22 PM ET

Sanofi Company Profile

Company profile explained

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Key Executives

Name Position
Belen Garijo Lopez Chief Executive Officer & Director
François-Xavier Roger Executive Vice President & Chief Financial Officer
Veronique Jaillet Executive VP & Interim Chief People Officer
Emmanuel Frenehard Executive VP & Chief Digital Officer
Erik Wallström Head of Therapeutic Area - Neurology Development
Fabrizio Gaudi Head of Austrian, German & Swiss Operations
Houman Ashrafian Executive VP & Head of Research & Development
Jamie Haney Executive Vice President & General Counsel
Karin Knobe TA Head of Rare Diseases & Rare Blood Disorders Development
Madeleine Roach Executive Vice President & Head of Business Operations
Michael Quigley Chief Scientific Officer & Head of Research
Olivier Charmeil Executive Vice President of General Medicines
Olivier Klaric Senior Vice President of Financing & Treasury
Pablo Sardi TA Head of Rare & Neurologic Diseases Research
Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Roy Papatheodorou Executive Vice President & General Counsel
Thomas Kudsk Larsen Head of Investor Relations & General Medicines
Thomas Triomphe Executive Vice President of Vaccines
Sanofi
Sanofi logo
Country France
IPO Date Apr 9, 2008
Industry Drug Manufacturers - General
Sector Healthcare
Employees 76,493
CEO Belén Garijo López

Contact Details

46, avenue de la Grande ArmEe Paris, IF 75017 France

Stock Details

Ticker Symbol SNYNF
Exchange OTC
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001121404
CUSIP Number 80105N105
ISIN Number FR0000120578
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.